Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Observational Clinical Study on the Safety and Efficacy of Anti-CD19/CD22 CAR NK Cells in Relapsed and Refractory B Cell Lymphoma

NCT03824964 is registered in ClinicalTrials.gov with Allife Medical Science and Technology Co., Ltd. as lead sponsor.

NCT NCT03824964
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03824964 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Observational Clinical Study on the Safety and Efficacy of Anti-CD19/CD22 CAR NK Cells in Relapsed and Refractory B Cell Lymphoma
Lead sponsor
Allife Medical Science and Technology Co., Ltd.
Phase
Phase 1
Overall status
Unknown status
Start date
February 1, 2019
Completion date
January 1, 2021
Enrollment
10 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

refractory b-cell lymphoma